אונגלייזה 5 מג
astrazeneca (israel) ltd - saxagliptin as hydrochloride - טבליות מצופות פילם - saxagliptin as hydrochloride 5 mg - saxagliptin - saxagliptin - monotherapy: onglyza is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.onglyza should not be used in patients with esrdcombination therapy: add-on combination: onglyza is indicated in patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin, a thiazolidinedione (tzd), or a sulfonylurea (su), when the single agent alone, with diet and exercise, does not provide adequate glycemic control.initial combination: onglyza is indicated for use as initial combination therapy with metformin, as an adjunct to diet and exercise, to improve glycemic control in patients with type 2 diabetes mellitus when dual saxagliptin and metformin therapy is appropriate.onglyza should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. in combination with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.
אונגלייזה 2.5 מג
astrazeneca (israel) ltd - saxagliptin as hydrochloride - טבליות מצופות פילם - saxagliptin as hydrochloride 2.5 mg - saxagliptin - saxagliptin - monotherapy: onglyza is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.onglyza should not be used in patients with esrdcombination therapy: add-on combination: onglyza is indicated in patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin, a thiazolidinedione (tzd), or a sulfonylurea (su), when the single agent alone, with diet and exercise, does not provide adequate glycemic control.initial combination: onglyza is indicated for use as initial combination therapy with metformin, as an adjunct to diet and exercise, to improve glycemic control in patients with type 2 diabetes mellitus when dual saxagliptin and metformin therapy is appropriate.onglyza should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. in combination with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.
פלומיסט קואדריוואלנט
astrazeneca (israel) ltd - a/darwin/9/2021 (h3n2)-like virus; a/victoria/4897/2022 (h1n1)pdm09-like virus; b/austria/1359417/2021 (b/victoria lineage)-like virus; b/phuket/3073/2013 (b/yamagata lineage)-like virus - ספריי לאף - b/phuket/3073/2013 (b/yamagata lineage)-like virus 7 ±0.5 log10 ffu^a / 0.2 ml; a/darwin/9/2021 (h3n2)-like virus 7 ±0.5 log10 ffu^a / 0.2 ml; b/austria/1359417/2021 (b/victoria lineage)-like virus 7 ±0.5 log10 ffu^a / 0.2 ml; a/victoria/4897/2022 (h1n1)pdm09-like virus 7 ±0.5 log10 ffu^a / 0.2 ml - influenza, inactivated, split virus or surface antigen - influenza, purified antigen - flumist quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by influenza a subtype viruses ad type b viruses contained in the vaccine. flumist quadrivalent is approved for use in persons 2 through 49 years of age.
קיטרודה 100 מג4 מל
merck sharp & dohme (israel - 1996) company ltd, israel - pembrolizumab - תרכיז להכנת תמיסה לאינפוזיה - pembrolizumab 25 mg/ml - pembrolizumab
אסטרופם 2 מג
novo nordisk ltd., israel - estradiol as hemihydrate - טבליות מצופות פילם - estradiol as hemihydrate 2 mg - estradiol - estradiol - hormone replacement therapy (hrt) for estrogen deficiency symptoms in postmenopausal women. prevention of osteoporosis in postmenopausal women at high risk of future fractures, who are tolerant of , or contraindicated for other medicinal products approved for the prevention of osteoporosis. estrofem is particularly for women who have been hysterectomized and therefore do not require combined estrogen/progestagen therapy.
אסטרופם 1 מג
novo nordisk ltd., israel - estradiol as hemihydrate - טבליות מצופות פילם - estradiol as hemihydrate 1 mg - estradiol - estradiol - hormone replacement therapy (hrt) for estrogen deficiency symptoms in postmenopausal women. prevention of osteoporosis in postmenopausal women at high risk of future fractures, who are tolerant of , or contraindicated for other medicinal products approved for the prevention of osteoporosis. estrofem is particularly for women who have been hysterectomized and therefore do not require combined estrogen/progestagen therapy.
אקטיבל
novo nordisk ltd., israel - estradiol as hemihydrate; norethisterone as acetate - טבליות מצופות פילם - estradiol as hemihydrate 1 mg; norethisterone as acetate 0.5 mg - norethisterone and estrogen - norethisterone and estrogen - hormone replacement therapy (hrt) for oestrogen deficiency symptoms in women more than one year after menopause. prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of , or contraindicated for, other medicinal products approved for the prevention of osteoporosis.
נובופם
novo nordisk ltd., israel - estradiol as hemihydrate; norethisterone acetate - טבליות מצופות פילם - estradiol as hemihydrate 1 mg; norethisterone acetate 1 mg - estradiol, combinations - estradiol, combinations - hormone replacement therapy (hrt) for estrogen deficiency symptoms in postmenopausal women with an intact uterus. prevention of osteoporosis in postmenopausal women at high risk of future fractures, who are tolerant of , or contraindicated for other medicinal products approved for the prevention of osteoporosis.
ווליבריס 5 מג
glaxo smith kline (israel) ltd - ambrisentan - טבליות מצופות פילם - ambrisentan 5 mg - ambrisentan - volibris is indicated for the treatment of patients with pulmonary arterial hypertension (pah) classified as who functional class ii and iii, to improve exercise capacity . efficacy has been shown in idiopathic pah (ipah) and in pah associated with connective tissue disease.
אנברל אבקה וממס
pfizer pharmaceuticals israel ltd - etanercept - אבקה וממס להכנת תמיסה להזרקה - etanercept 25 mg/vial - etanercept - etanercept - * rheumatoid arthritis:enbrel is indicated for the treatment of active rhematoid arthritis in adults when the response to disease-modifying antirheumatic drugs (dmards) including methotrexate (unless contraindicated) has been inadequate.. enbrel can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone. reducing signs and symptoms and inhibiting the progression of structural damage in patients with moderately to severely active rheumatoid arthritis.enbrel, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function.* polyarticular juvenile idiopathic arthritis: treatment of active polyarticular juvenile idiopathic arthritis in children and adolescents from the age of 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. enbrel has not been studied in children aged less than 2 years.* psoriatic arthritistreatment of ac